Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Chemomab Therapeutics Ltd. is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need [3] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference, with a prerecorded presentation available starting September 5, 2025 [1][2] Company Overview - Chemomab is developing nebokitug (CM-101), a first-in-class dual activity monoclonal antibody targeting the soluble protein CCL24, which plays a role in fibrosis and inflammation [3] - Nebokitug has shown disease-modifying potential and a favorable safety profile in clinical and preclinical studies, indicating its potential to treat severe fibro-inflammatory diseases [3] - The company has reported positive results from five clinical trials of nebokitug, particularly from the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) [3] - Chemomab is preparing for a potential Phase 3 trial in PSC, which will be a single pivotal trial with a clinical event primary endpoint, aiming for full regulatory approval [3] - Nebokitug has received Orphan Drug designation from the FDA and EMA, as well as Fast Track designation from the FDA for the treatment of PSC [3] - The program for treating systemic sclerosis with nebokitug has an open U.S. IND [3]